Aileen Ryan

436 total citations
21 papers, 230 citations indexed

About

Aileen Ryan is a scholar working on Oncology, Biotechnology and Genetics. According to data from OpenAlex, Aileen Ryan has authored 21 papers receiving a total of 230 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 7 papers in Biotechnology and 6 papers in Genetics. Recurrent topics in Aileen Ryan's work include Cancer Immunotherapy and Biomarkers (14 papers), Cancer Research and Treatments (7 papers) and Immunotherapy and Immune Responses (6 papers). Aileen Ryan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Cancer Research and Treatments (7 papers) and Immunotherapy and Immune Responses (6 papers). Aileen Ryan collaborates with scholars based in United States, Australia and Switzerland. Aileen Ryan's co-authors include Toni Ricciardi, Ralph Venhaus, Mary Macri, Paul Schwarzenberger, Gavin P. Dunn, David A. Reardon, Jörg Dietrich, Hui Gan, Andrew J. Park and Timothy F. Cloughesy and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Aileen Ryan

21 papers receiving 226 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aileen Ryan United States 9 173 106 96 50 45 21 230
Toni Ricciardi United States 9 173 1.0× 106 1.0× 96 1.0× 50 1.0× 45 1.0× 25 233
Mary Macri United States 9 169 1.0× 105 1.0× 96 1.0× 48 1.0× 43 1.0× 20 225
Sanne H. Hendriks Netherlands 5 156 0.9× 112 1.1× 25 0.3× 30 0.6× 51 1.1× 7 266
Yumiko Higuchi Japan 10 167 1.0× 166 1.6× 54 0.6× 48 1.0× 92 2.0× 30 305
Hong Hoi Ting United Kingdom 7 186 1.1× 104 1.0× 14 0.1× 42 0.8× 158 3.5× 9 388
Carolyn G. Chapman United States 6 131 0.8× 87 0.8× 36 0.4× 96 1.9× 51 1.1× 7 217
Laura Deedigan Ireland 7 85 0.5× 54 0.5× 121 1.3× 38 0.8× 172 3.8× 8 291
Qiang Feng China 7 71 0.4× 94 0.9× 22 0.2× 20 0.4× 120 2.7× 13 280
Megan Wachsmann United States 7 167 1.0× 73 0.7× 9 0.1× 16 0.3× 79 1.8× 11 273
Fransien de Boer Netherlands 7 92 0.5× 115 1.1× 130 1.4× 17 0.3× 89 2.0× 14 324

Countries citing papers authored by Aileen Ryan

Since Specialization
Citations

This map shows the geographic impact of Aileen Ryan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aileen Ryan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aileen Ryan more than expected).

Fields of papers citing papers by Aileen Ryan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aileen Ryan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aileen Ryan. The network helps show where Aileen Ryan may publish in the future.

Co-authorship network of co-authors of Aileen Ryan

This figure shows the co-authorship network connecting the top 25 collaborators of Aileen Ryan. A scholar is included among the top collaborators of Aileen Ryan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aileen Ryan. Aileen Ryan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Dung‐Tsa, Joshua K. Sabari, Jonathan R. Thompson, et al.. (2024). Abstract CT052: A phase IB study of mRNA-based active cancer vaccine, BI1361849, combined with durvalumab and tremelimumab immunotherapy in patients with non-small cell lung cancer (NSCLC). Cancer Research. 84(7_Supplement). CT052–CT052. 5 indexed citations
2.
Middleton, Mark R., Ioannis Karydis, Xin Lü, et al.. (2023). Long-term outcomes from adding durvalumab to neoadjuvant treatment of operable gastroesophageal cancers: Results from a multicenter study LUD2015-005.. Journal of Clinical Oncology. 41(4_suppl). 398–398. 2 indexed citations
3.
Zamarin, Dmitriy, Kunle Odunsi, Emese Zsíros, et al.. (2022). Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Phase 2 results.. Journal of Clinical Oncology. 40(16_suppl). 2600–2600. 5 indexed citations
4.
Slingluff, Craig L., Ileana S. Mauldin, Elizabeth Gaughan, et al.. (2021). 337 Intratumoral immune therapy for recurrent breast cancer with polyICLC, and tremelimumab combined with systemic durvalumab. Regular and Young Investigator Award Abstracts. A363–A363. 2 indexed citations
5.
6.
7.
Reardon, David A., Thomas Kaley, Jörg Dietrich, et al.. (2019). Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).. Journal of Clinical Oncology. 37(15_suppl). 2032–2032. 43 indexed citations
8.
Sabari, Joshua K., Paul Schwarzenberger, Toni Ricciardi, et al.. (2019). Abstract B209: Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC). Cancer Immunology Research. 7(2_Supplement). B209–B209. 12 indexed citations
9.
Callahan, Margaret K., Kunle Odunsi, Mario Sznol, et al.. (2019). Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors. Cancer Immunology Research. 7(2_Supplement). A006–A006. 1 indexed citations
10.
Zamarin, Dmitriy, Kunle Odunsi, Brian M. Slomovitz, et al.. (2019). Abstract A022: Phase 1/2 study to evaluate systemic durvalumab (durva) + intraperitoneal ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC). Cancer Immunology Research. 7(2_Supplement). A022–A022. 1 indexed citations
11.
Gandhi, Leena, Paul Schwarzenberger, Toni Ricciardi, et al.. (2018). Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 36(15_suppl). TPS9107–TPS9107. 13 indexed citations
12.
O’Cearbhaill, Roisin E., Anita Wolfer, Paul DiSilvestro, et al.. (2018). A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC). Annals of Oncology. 29. viii337–viii337. 14 indexed citations
13.
Reardon, David A., Thomas Kaley, Jörg Dietrich, et al.. (2018). ATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) + BEVACIZUMAB (BEV) IN BEV-NAÏVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology. 20(suppl_6). vi10–vi10. 7 indexed citations
14.
Callahan, Margaret K., Kunle Odunsi, Mario Sznol, et al.. (2017). Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, DUR) + tremelimumab (TRE) in patients with advanced solid tumors.. Journal of Clinical Oncology. 35(15_suppl). 3069–3069. 23 indexed citations
15.
Reardon, David A., Thomas Kaley, Jörg Dietrich, et al.. (2017). Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: An update.. Journal of Clinical Oncology. 35(15_suppl). 2042–2042. 41 indexed citations
16.
Slingluff, Craig L., Paul Schwarzenberger, Toni Ricciardi, et al.. (2017). Phase 1/2 study of in situ vaccination with tremelimumab + intravenous (IV) durvalumab + poly-ICLC in patients with select relapsed, advanced cancers with measurable, biopsy-accessible tumors.. Journal of Clinical Oncology. 35(15_suppl). TPS3106–TPS3106. 4 indexed citations
17.
Reardon, David A., Thomas Kaley, Jörg Dietrich, et al.. (2017). ATIM-12. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH BEVACIZUMAB (BEV)-REFRACTORY RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology. 19(suppl_6). vi28–vi28. 8 indexed citations
18.
19.
20.
Reardon, David A., Thomas Kaley, Jörg Dietrich, et al.. (2016). Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM).. Journal of Clinical Oncology. 34(15_suppl). TPS2080–TPS2080. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toni Ricciardi Breakdown of academic impact, for papers by Mary Macri Breakdown of academic impact, for papers by Sanne H. Hendriks Breakdown of academic impact, for papers by Yumiko Higuchi Breakdown of academic impact, for papers by Hong Hoi Ting Breakdown of academic impact, for papers by Carolyn G. Chapman Breakdown of academic impact, for papers by Laura Deedigan Breakdown of academic impact, for papers by Qiang Feng Breakdown of academic impact, for papers by Megan Wachsmann Breakdown of academic impact, for papers by Fransien de Boer
Rankless by CCL
2026